JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
FORT LAUDERDALE – Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company with a market capitalization of $4.16 million engaged in the development of life-saving medicines, has announced the completion of additional studies that support its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) as a potential treatment for human hepatocellular carcinoma (HCC), a common and deadly form of liver cancer. According to InvestingPro analysis, the company appears undervalued based on its Fair Value metrics, despite its stock falling nearly 99% over the past year.
The company’s recent studies have focused on optimizing the expression levels of two versions of its mRNA product—full-length K1.1c and truncated K1.1d—in HCC tumors in mice. These mRNA sequences, when encapsulated in specially designed Lipid Nanoparticles, were delivered to orthotopic engrafted HCC tumors in mice. Systemic administration showed that the full-length K1.1c reduced the growth of various human HCC tumors in mice and was well-tolerated.
A preliminary study of the truncated version, K1.1d, indicated significant anti-tumor activity in HCC models in mice, suggesting that this shorter mRNA could be highly expressed in engrafted tumors and potentially offer better efficacy at lower doses. Further animal studies are underway to determine the optimal dosing of K1.1d.
Dr. Steve Slilaty, CEO of Sunshine Biopharma, highlighted the innovative nature of their work, stating, "We are pushing the frontier of mRNA therapy for cancer with our novel mRNA-LNP formulation."
In addition to its work on mRNA-LNP formulations for cancer treatment, Sunshine Biopharma has a market presence with 70 generic prescription drugs in Canada and plans to launch 13 additional drugs in 2025, including NIOPEG®, a biosimilar of the drug NEULASTA®. Financial data from InvestingPro shows the company achieved impressive revenue growth of 62% in the last twelve months, with a healthy gross profit margin of 31%. While the company maintains strong liquidity with a current ratio of 5.74, investors should note it’s currently not profitable and is burning through cash rapidly.
The company’s forward-looking statements, as outlined in the press release, involve risks and uncertainties that could result in significantly different outcomes or results than anticipated. These risks are detailed in the company’s filings with the U.S. Securities and Exchange Commission (SEC). For deeper insights into SBFM’s financial health, valuation metrics, and 8 additional key ProTips, visit InvestingPro.
This report is based on a press release statement from Sunshine Biopharma Inc. and does not include any promotional content or endorsement of claims. The information presented is intended to provide a factual update on the company’s recent developments in drug research and market offerings.
In other recent news, Sunshine Biopharma Inc. has announced a strategic agreement to market two new generic antibiotics in Canada through its subsidiary, Nora Pharma, pending regulatory approval. This move is part of the company’s efforts to expand its presence in the Canadian market, which currently includes a portfolio of 70 generic prescription drugs. Additionally, Sunshine Biopharma has introduced Prucalopride, a generic gastrointestinal drug, in Canada, with plans to release another drug in this category within the next nine months. The company is also launching two generic prescription drugs, Olanzapine and its orally disintegrating tablet form, for treating schizophrenia and bipolar disorders. Furthermore, Sunshine Biopharma has appointed Mr. Michel Roy as its new Chief Commercial Officer, bringing his extensive experience in the pharmaceutical industry to the company. The company continues to focus on proprietary drug development, targeting areas such as liver cancer and SARS Coronavirus infections. These developments reflect Sunshine Biopharma’s ongoing expansion and diversification in the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.